Quick Answer
Co-Diagnostics, Inc. reported Cash and Equivalents of $11.88 million for fiscal year 2025.
Co-Diagnostics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $11.88M | +304.7% |
| 2024 | $2.94M | -80.3% |
| 2023 | $14.92M | -35.1% |
| 2022 | $22.97M | -74.1% |
| 2021 | $88.61M | +106.2% |
| 2020 | $42.98M | +4711.9% |
| 2019 | $893.1K | -6.0% |
| 2018 | $950.2K | -73.1% |
| 2017 | $3.53M | +253.9% |
| 2016 | $998.7K | +2854.4% |
| 2015 | $33.8K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.44M | +6.0% | +3.0% |
| June 30, 2025 | $11.12M | -19.8% | +484.1% |
| March 31, 2025 | $1.90M | -91.8% | -35.2% |
| December 31, 2024 | $2.94M | -80.3% | -72.8% |
| September 30, 2024 | $10.80M | +5.4% | -22.1% |
| June 30, 2024 | $13.86M | +0.2% | -40.0% |
| March 31, 2024 | $23.10M | +263.2% | +54.9% |
| December 31, 2023 | $14.92M | -35.1% | +45.7% |
- Co-Diagnostics, Inc. showed an increase of +304.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2015–2025 period, Co-Diagnostics, Inc.’s cash and equivalents has grown by 35056.4% (from $33.8 thousand to $11.88 million).
- The most recent figure is from Co-Diagnostics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: